Digital pharmacy company Phlo Technologies has announced the acquisition of the UK branch of US-based healthcare platform Truepill, following Phlo’s announcement last month of £10 million in Series A funding.
Phlo has acquired Truepill’s partnerships with several of the UK’s digital health providers, including The Lowdown (contraceptive advice and support platform); Levels (metabolic health-focused software company); Daye (gynaecological health platform); Hanx (focusing on contraception and intimate care); and Veri (metabolic health platform).
They have also acquired Truepill UK’s technology stack, including a “comprehensive” set of Application Programming Interfaces and prescribing technology, and Phlo Digital Pharmacy has acquired Truepill’s NHS patient base.
Once integrated, Phlo’s technology is set to “facilitate a variety of digital services such as prescribing, dispensing and delivery of prescribed and off-the-shelf medications directly to platform users”.
The consolidation is to allow Phlo to expand its geographic footprint, with future plans including the launch of same-day on-demand medication delivery in Manchester alongside existing services in London and Birmingham. In terms of further growth, Phlo is to support Truepill’s US partners should any look to launch into the UK market, as part of the commercial partnership attached to the deal.
Nadeem Sarwar, founder and CEO of Phlo, said: “Phlo’s acquisition of Truepill UK marks a hugely significant moment in the evolution of digital healthcare in the UK… Following our Series A raise, Phlo is in a stronger position than ever to lead digital transformation in the pharmacy sector and to play a pivotal role in improving health outcomes in the UK.”
